- Home
- ARHS vs VRDN Comparison
ARHS vs VRDN Comparison
Compare ARHS & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARHS
- VRDN
- Stock Information
- Founded
- ARHS 1986
- VRDN 2006
- Country
- ARHS United States
- VRDN United States
- Employees
- ARHS 2630
- VRDN N/A
- Industry
- ARHS Other Specialty Stores
- VRDN Medical Specialities
- Sector
- ARHS Consumer Discretionary
- VRDN Health Care
- Exchange
- ARHS Nasdaq
- VRDN Nasdaq
- Market Cap
- ARHS 1.6B
- VRDN 1.5B
- IPO Year
- ARHS 2021
- VRDN N/A
- Fundamental
- Price
- ARHS $11.45
- VRDN $18.80
- Analyst Decision
- ARHS Buy
- VRDN Strong Buy
- Analyst Count
- ARHS 13
- VRDN 11
- Target Price
- ARHS $11.71
- VRDN $38.80
- AVG Volume (30 Days)
- ARHS 1.7M
- VRDN 850.8K
- Earning Date
- ARHS 11-06-2025
- VRDN 11-11-2025
- Dividend Yield
- ARHS N/A
- VRDN N/A
- EPS Growth
- ARHS N/A
- VRDN N/A
- EPS
- ARHS 0.50
- VRDN N/A
- Revenue
- ARHS $1,335,951,000.00
- VRDN $305,000.00
- Revenue This Year
- ARHS $8.41
- VRDN N/A
- Revenue Next Year
- ARHS $7.04
- VRDN $35,092.81
- P/E Ratio
- ARHS $22.04
- VRDN N/A
- Revenue Growth
- ARHS 4.76
- VRDN 5.90
- 52 Week Low
- ARHS $6.61
- VRDN $9.90
- 52 Week High
- ARHS $13.97
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- ARHS 53.93
- VRDN 51.88
- Support Level
- ARHS $10.72
- VRDN $17.91
- Resistance Level
- ARHS $11.32
- VRDN $20.51
- Average True Range (ATR)
- ARHS 0.40
- VRDN 0.92
- MACD
- ARHS -0.12
- VRDN -0.14
- Stochastic Oscillator
- ARHS 56.85
- VRDN 34.04
About ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).